×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu
Broker News

Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

Broker News

SXY – Macquarie rates the stock as Outperform

January 25, 2021 - by Broker News

Senex Energy’s CSG production continues to ramp up gradually, Macquarie notes. The broker sees production broadly tripling to FY23. Outperform and 45c target retained.

Read More
Broker News

FPH – UBS rates the stock as Sell

January 25, 2021 - by Broker News

Fisher & Paykel Healthcare Corp’s latest trading update showed larger-than-expected covid-led hospital sales. UBS sees a material drop in earnings over the next 18 months and maintains its Sell rating. Target rises to NZ$23.40 from NZ$21.35.

Read More
Broker News

DCN – Macquarie rates the stock as Underperform

January 25, 2021 - by Broker News

Dacian Gold’s December quarter report showed production in line with a pre-release and costs -10% lower than expected. Underperform and 34c target retained.

Read More
Broker News

PPT – Credit Suisse rates the stock as Outperform

January 25, 2021 - by Broker News

Perpetual’s business update was “disappointing”. As a result, earnings have been downgraded by -4-6% across the forecast period. Outperform rating is maintained with the target falling to $37.50 from $39.

Read More
Broker News

BXB – Morgans rates the stock as Add

January 25, 2021 - by Broker News

BXB remains one of Morgans key picks in the large-cap space due to a global leading market position and strong defensive characteristics. The broker maintains its Add rating. The target price falls to $11.90 from $12.16.

Read More
Broker News

RMD – UBS rates the stock as Buy

January 22, 2021 - by Broker News

UBS incorporates a 10% share buyback into forecasts, after assuming no major increases in debt levels due to any significant near-term acquisitions. The Buy rating is unchanged. The target price is increased to $US241 from US$210.

Read More
Broker News

IPL – Credit Suisse rates the stock as Downgrade to Neutral

January 22, 2021 - by Broker News

Fertiliser prices are strengthening and even with a weaker USD, have created a stronger near-term outlook for Incitec Pivot, suggests Credit Suisse. Target rises to $2.73 from $2.70.

Read More
Broker News

S32 – Morgans rates the stock as Downgrade to Hold

January 22, 2021 - by Broker News

Despite a second quarter result ahead of estimates, Morgans lowers South32’s rating to Hold from Add, due to a recent share price rally. The broker reduces the target price to $2.60 from $2.65.

Read More
Broker News

SSR – UBS rates the stock as Buy

January 21, 2021 - by Broker News

SSR Mining’s guidance for 2021 proved in-line with UBS’s forecasts, but costs are expected to be higher and more investments are on the agenda (some $100m more). New price target of $28 compares with $30 previously. Buy rating retained.

Read More
Broker News

BHP – Morgans rates the stock as Hold

January 21, 2021 - by Broker News

Morgans describes the overall second quarter operational result as consistent. The analyst highlights the strength of iron ore spot prices is supplying a substantial earnings tailwind and an impressive dividend profile. Target price is $40.55.

Read More
Broker News

ANN – Credit Suisse rates the stock as Outperform

January 21, 2021 - by Broker News

Ansell will report its first-half results on 16 February and expects to deliver organic growth above 20%, higher than Credit Suisse’s previous forecast of 14%. Outperform retained. Target is raised to $45.50 from $45.

Read More
Broker News

BRG – Morgans rates the stock as Add

January 21, 2021 - by Broker News

Morgans expects a strong result, forecasting around 16% earnings (EBIT) growth and believes a strong first half outcome could make FY21 guidance look conservative. The Add rating and $29.18 target are unchanged.

Read More
Broker News

ANN – UBS rates the stock as Neutral

January 21, 2021 - by Broker News

Ansell released a trading update with higher growth guidance for the full financial year. UBS analysts, in response, have increased forecasts by 4% for FY21. Target price is $39.60. Neutral rating retained.

Read More
Broker News

BHP – Credit Suisse rates the stock as Outperform

January 21, 2021 - by Broker News

Marking to markets for December quarter commodity prices causes Credit Suisse to lift its FY21 earnings 3%. All major catalysts except for commodity prices remain unchanged and the broker retains its $40 target. Outperform.

Read More
Broker News

RIO – UBS rates the stock as Neutral

January 20, 2021 - by Broker News

Rio Tinto finished 2020 in line with its guidance and ahead of UBS’s estimates with total iron ore shipments at 330.6mt. A final dividend of US$3.70 per share is forecast. The Neutral rating and target price of $115 are unchanged.

Read More
Broker News

HUB – Credit Suisse rates the stock as Upgrade to Outperform

January 20, 2021 - by Broker News

Hub24’s second-quarter funds under administration (FuA) at $22bn were up 16% on a quarterly basis and 3% ahead of Credit Suisse’s forecast. Rating is upgraded to Outperform from Neutral with the target price rising to $26 from $21.50.

Read More
Broker News

BIN – Morgans rates the stock as Hold

January 20, 2021January 20, 2021 - by Broker News

Bingo Industries has received a takeover offer from CPE Capital. Morgans lifts the target price to $3.50 to align with the indicative offer price. The Hold rating is maintained.

Read More
Broker News

HMC – Morgans rates the stock as Add

January 20, 2021 - by Broker News

Morgans notes Home Consortium had an active end to 2020 after spinning off the HomeCo Daily Needs REIT ((HDN)), new acquisitions and a capital raising. The Add rating is unchanged and the target price increased to $4.27 from $3.60.

Read More
Broker News

BIN – Credit Suisse rates the stock as Upgrade to Outperform

January 20, 2021January 20, 2021 - by Broker News

CS believes Bingo Industries has the potential to generate $231m in operating income by FY23 and based on the FY23 forecast, the fundamental value of the stock could be over $4 per share. Rating is upgraded to Outperform from Neutral with the target rising to $3 from $2.40.

Read More
Broker News

ELD – Citi rates the stock as Buy

January 19, 2021 - by Broker News

Citi analysts point out the 2020/21 winter crop is set to beat expectations. The broker sees plenty of justification for its above-consensus forecasts, which are supporting the Buy rating and $13 price target.

Read More
Broker News

SUL – Credit Suisse rates the stock as Outperform

January 19, 2021 - by Broker News

Super Retail Group noted a net profit rise of 137% in the first half with sales revenue increasing by 23%. Credit Suisse has more confidence than the market in the company’s FY22 earnings prospects. Target price is $13.19.

Read More
Broker News

CGF – Morgans rates the stock as Hold

January 19, 2021 - by Broker News

Morgans updates the Insurance/Diversified Financials sector earnings on a mark-to-market basis and a broad review of earnings assumptions, and believes Challenger is one of the best positioned of the large cap stocks to produce solid/stable results. Target price is $6.80.

Read More
Broker News

RIO – Macquarie rates the stock as Outperform

January 18, 2021 - by Broker News

Macquarie has marked to market December quarter commodity prices and foreign exchange rates and remains positive on copper exposure going into 2021. for Rio Tinto, the major driver for the diversified miner remains buoyant iron ore prices. The Outperform rating and target of $127 are unchanged.

Read More
Broker News

STO – Citi rates the stock as Downgrade to Neutral from Buy

January 18, 2021 - by Broker News

Energy analysts at Citi have increased price expectations for cude oil and LNG. The 2021 Brent oil price forecast moved to US$59/bbl from US$52/bbl. The team sees oil peaking at US$61/bbl in 1Q22. The new price target for Santos is $7.58. Rating has been downgraded to Neutral from Buy.

Read More
Broker News

PDL – Morgan Stanley rates the stock as Overweight

January 18, 2021 - by Broker News

Pendal Group’s December quarter was mixed, observes Morgan Stanley, with better than expected funds under management (mainly driven by investment performance) offset by lower than anticipated total quarter flows. Overweight rating retained with a target of $7.30.

Read More
Broker News

ALD – Macquarie rates the stock as Outperform

January 15, 2021 - by Broker News

Backed by lower crude premiums, Ampol’s Lytton refinery saw its December quarter operating loss go down to -$4m, a far cry from the -$82m loss seen in the third quarter. Outperform retained with a target price of $34.65.

Read More
Broker News

PME – UBS rates the stock as Neutral

January 15, 2021 - by Broker News

UBS highlights Pro Medicus’s radiology pipeline conversion over 6 years is significantly above UBS’s estimate and suggests continuing momentum into the second half. Neutral rating is reaffirmed with a target of $32.

Read More
Broker News

COE – Morgans rates the stock as Add

January 15, 2021 - by Broker News

Morgans suggest now is an opportune time to invest in the oil and gas sector after gaining further conviction both oil and LNG markets have moved off their lows. The Add rating and target price of $0.43 are unchanged for Cooper Energy.

Read More
Broker News

WSA – Macquarie rates the stock as Outperform

January 14, 2021January 14, 2021 - by Broker News

Macquarie’s Commodities Strategy team has upgraded its short term nickel price forecasts by 7-8%, medium-term by 10-13% and long-term by 3%. WSA’s rating remains Outperform with a price target of $3.30, up from $2.80.

Read More
Broker News

PMV – Citi rates the stock as Neutral

January 14, 2021 - by Broker News

Premier Investments’ first half guidance of 75-85% retail earnings (EBIT) growth was well ahead of Citi’s expectations and was driven by gross margin expansion and operating leverage. Citi maintains a Neutral rating and lifts the target price to $25 from $20.60.

Read More
Broker News

UNI – Morgans rates the stock as Add

January 14, 2021 - by Broker News

In the wake of a first half trading update from Universal Store Holdings, Morgans makes 12-20% EPS upgrades across the forecast years and raises the price target to $6.93 from $6.05.

Read More
Broker News

NVX – Morgans rates the stock as Downgrade to Hold from Add

January 13, 2021 - by Broker News

Morgans has pulled back its rating for Novonix to Hold from Speculative Buy. The target price has remained unchanged at $1.33.

Read More
Broker News

ALU – Credit Suisse rates the stock as Outperform

January 13, 2021 - by Broker News

Earnings estimates have been reduced and the analysts conclude their initiation of coverage with an Outperform rating and $42 price target has proved to be “a half too early”.

Read More
Broker News

ARB – Macquarie rates the stock as Neutral

January 13, 2021 - by Broker News

Macquarie finds the immediate outlook for ARB remains positive, carried by a strong orderbook, but also believes visibility into FY22 is rather low. Neutral rating retained. Price target improves to $33.50.

Read More
Broker News

QBE – Morgan Stanley rates the stock as Overweight

January 12, 2021 - by Broker News

Now it has transpired that reinsurance renewal fees will be less of a burden than feared in 2021, Morgan Stanley analysts suggest investor attention can now focus on the quality of earnings. Target price is $11.50.

Read More
Broker News

ASX – Credit Suisse rates the stock as Underperform

January 12, 2021 - by Broker News

Credit Suisse found the ASX’s December trading activity update (slightly) weaker-than-projected, and therefore the current share price is considered too expensive. Target price is $71.00.

Read More
Broker News

QBE – Macquarie rates the stock as Underperform

January 12, 2021 - by Broker News

Macquarie has updated its thoughts and modeling for QBE Insurance Group. Macquarie analysts do not expect FY21 guidance and forecast only a 4c dividend in 2H20. The broker cuts its price target to $7.70 from $8 on further reduction in forecasts.

Read More
Broker News

CHC – Morgan Stanley rates the stock as Overweight

January 11, 2021 - by Broker News

Morgan Stanley has upgraded its price target for Charter Hall, to $16.88 from $13.10, on anticipation of stronger funds inflows as investors are increasingly appreciating the unique characteristics on offer.

Read More
Broker News

SYD – Morgans rates the stock as Add

January 11, 2021 - by Broker News

Analysts at Morgans have updated their modeling and assumptions for SYD. They remain confident a sustained recovery lays ahead on the back of vaccine roll-outs internationally. Add rating retained. Target price is $6.95.

Read More
Broker News

ANP – Morgans rates the stock as Initiation of coverage with Add

January 8, 2021January 8, 2021 - by Broker News

Stockbroker Morgans has initiated coverage of Antisense Therapeutics with a Speculative Buy rating and a maiden price target of 37.7c.

Read More

Posts navigation

1 2 … 235 Next

Recently Added

  • A Bumpy and Uncertain Road to Recovery
  • Bega Now Big Cheese in Oz Food & Beverage Sector
  • Ampol Deal Looking Less Likely as Canadians Weigh Options
  • Dividend Yields Expected to Increase in 2021
  • Evening Report: Aussie shares lift despite light trading volumes
  • SXY – Macquarie rates the stock as Outperform
  • FPH – UBS rates the stock as Sell
  • Lunch Report: Market near 11-month high

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Financial Services Guide | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Cup.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Star.

DOWNLOAD RESEARCH REPORT

A Laser-Like Focus on Adding Value

Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Truck.